Hemab Therapeutics presented interim clinical data for HMB-002 showing ≥2.4‑fold peak increases in VWF and FVIII and normalization of thrombin generation and APTT, and announced HMB-003 for heavy menstrual bleeding. The results provide a proof‑of‑concept for a novel factor mimetic that could address unmet needs in von Willebrand disease and expand treatment options for heavy menstrual bleeding. Who is involved: Hemab Therapeutics (presenter), ISTH 2026 congress attendees, investigators of the HMB-002 study.. Likely next: Further clinical testing will be required to establish efficacy and safety before regulatory submission.. At the ISTH 2026 congress, Hemab Therapeutics released clinical data indicating that its investigational factor mimetic HMB-002 produced dose‑dependent increases of at least 2.4‑fold in von Willebrand factor and factor VIII, normalized thrombin generation and activated partial thromboplastin time. The company also introduced HMB-003, a new candidate targeting heavy menstrual bleeding. The data suggest a mechanistic basis for further development, though no efficacy or safety endpoints were disclosed. Sectors affected: Von Willebrand factor therapeutics Historical parallels: FDA approval of recombinant von Willebrand factor (Vonvendi) in 2015 EMA approval of desmopressin intranasal spray for VWD in 2002
INTELLIGENCE
Social Pulse
AI estimate · not scraped